The TissueGEN project focuses on the production of an in vitro human disease tissue platform technology to enable and accelerate the development of regenerative medicine therapies for a diverse range of diseases. The concept will be realized by the in vitro generation of 3D human tissues cultured from human induced Pluripotent Stem (iPS) cells. A bioreactor will be constructed using a range of innovative microfluidic techniques to produce systems compatible with analysis systems commonly used in laboratories worldwide (e.g. well plate format). The development of a platform technology producing 3D human tissue disease cultures will enable the generation of fully differentiated cell types and thus allow diseases to be effectively modeled at a population relevant scale in 3D human tissues in vitro.
The research receives funding from the FP7-Health Program (grant agreement no. 278955).